Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STTK 
Shattuck Labs Inc (STTK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: STTK (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $1.46
1 Year Target Price $1.46
| 2 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 74.7% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 47.90M USD | Price to earnings Ratio - | 1Y Target Price 1.46 |
Price to earnings Ratio - | 1Y Target Price 1.46 | ||
Volume (30-day avg) 5 | Beta 1.64 | 52 Weeks Range 0.69 - 3.95 | Updated Date 08/15/2025 |
52 Weeks Range 0.69 - 3.95 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.245 | Actual -0.24 |
Profitability
Profit Margin - | Operating Margin (TTM) -1621.58% |
Management Effectiveness
Return on Assets (TTM) -41.77% | Return on Equity (TTM) -71.9% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -16489074 | Price to Sales(TTM) 10.4 |
Enterprise Value -16489074 | Price to Sales(TTM) 10.4 | ||
Enterprise Value to Revenue 18.32 | Enterprise Value to EBITDA -3.62 | Shares Outstanding 47903200 | Shares Floating 24146965 |
Shares Outstanding 47903200 | Shares Floating 24146965 | ||
Percent Insiders 14.36 | Percent Institutions 57.84 |
Upturn AI SWOT
Shattuck Labs Inc
Company Overview
History and Background
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of transformative medicines for the treatment of cancer and autoimmune disease. Founded in 2011, it focuses on developing Agonist Redirected Checkpoint (ARCu00ae) therapeutics.
Core Business Areas
- ARCu00ae Platform Development: Developing and researching new molecules using their ARCu00ae platform.
- Oncology: Developing therapies to treat different forms of cancer.
- Immunology: Developing therapies targeting autoimmune and inflammatory disorders.
Leadership and Structure
The leadership team includes Josie Cook, Chief Executive Officer and Gregg Beloff, Chief Financial Officer. The company has a board of directors that oversees operations.
Top Products and Market Share
Key Offerings
- SL-172154 (SIRPu03b1-Fc-CD40L): A lead clinical program targeting advanced ovarian cancer and other solid tumors. Currently in Phase 1 clinical trials. Competitors include other immuno-oncology approaches and checkpoint inhibitors from companies like Merck (MRK) and Bristol Myers Squibb (BMY).
- SL-279252 (PD-L1-Fc-OX40): Another clinical program being developed for cancer. This also is in Phase 1 clinical trials. Competitors include other immuno-oncology approaches and checkpoint inhibitors from companies like Roche (RHHBY) and AstraZeneca (AZN).
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and focused on developing new therapies for diseases with unmet medical needs. It involves significant research and development expenditure with uncertain outcomes and long development timelines.
Positioning
Shattuck Labs is positioned as a company developing novel immunotherapies using its ARCu00ae platform, competing with larger pharmaceutical and biotech companies.
Total Addressable Market (TAM)
The TAM for cancer and autoimmune disease therapies is substantial, estimated in the hundreds of billions of dollars. Shattuck Labs is focused on a niche within this market, targeting specific mechanisms of action with its ARCu00ae platform.
Upturn SWOT Analysis
Strengths
- Novel ARCu00ae platform technology
- Experienced leadership team
- Proprietary technology
- Focus on unmet medical needs
Weaknesses
- Reliance on early-stage clinical programs
- High cash burn rate
- Dependence on external funding
- Limited commercialization experience
Opportunities
- Positive clinical trial results
- Strategic partnerships with larger pharmaceutical companies
- Expansion of the ARCu00ae platform to new targets
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from established therapies
- Regulatory hurdles
- Economic downturn affecting funding
Competitors and Market Share
Key Competitors
- MRK
- BMY
- AZN
- RHHBY
Competitive Landscape
Shattuck Labs faces significant competition from established pharmaceutical companies with greater resources. Its competitive advantage lies in its novel ARCu00ae platform, but it needs to demonstrate clinical efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by R&D to bring drugs to market.
Future Projections: Future growth depends on the successful clinical development and commercialization of its ARCu00ae therapeutics. Analyst estimates vary, but generally project revenue growth upon successful commercialization.
Recent Initiatives: Recent initiatives include advancing clinical trials for SL-172154 and SL-279252, and exploring new applications for the ARCu00ae platform.
Summary
Shattuck Labs is a high-risk, high-reward biotechnology company focused on novel immunotherapies. Its ARCu00ae platform offers potential advantages, but clinical success is uncertain. The company faces significant competition and requires substantial funding to continue operations. Success is dependent on clinical trials progressing to successful commercial outcomes.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Shattuck Labs Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2020-10-09 | Co-Founder, CEO & Director Dr. Taylor H. Schreiber M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.shattucklabs.com |
Full time employees 44 | Website https://www.shattucklabs.com | ||
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically validated targets. In addition, the company is involved in the advancement of its lead TRIM7 inhibitors through preclinical development as future internal pipeline candidates in oncology. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.